clinical trial · NCT04790175
Samsca Post-marketing General Drug Use-results Survey in Patients with Hyponatremia in SIADH
Otsuka Pharmaceutical Co., Ltd.·—·recruiting·n = 300
Antidiuretic Hormone, Inappropriate SecretionTolvaptan (SAMSCA)
brief summary
The purpose of this study is to confirm the safety of tolvaptan in patients with hyponatremia in syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Japan
started
Mar 29, 2021
primary completion
Aug 1, 2028
completion
Jan 1, 2030
last updated
Mar 24, 2025
official title
Samsca Post-marketing General Drug Use-results Survey in Patients with Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in Japan
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol